Business
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
Primary endpoint of QUILT-3.078 is overall survival; median overall survival has not yet been reached, with 19 of 23 enrolled patients alive as of January
About this update from Immunitybio, Inc.
[{"type":"text","content":"\n\nPrimary endpoint of QUILT-3.078 is overall survival; median overall survival has not yet been reached, with 19 of 23 enrolled patients alive as of January 22, 2026\n\n\n\nFourteen patients have evaluable data, with the longest survival from time of disease recurrence reaching 12 months to date and ongoing\n\n\n\nBaseline mean absolute lymphocyte count (ALC) among these 14 patients was 0.9 x 103/uL, confirming severe lymphopenia at enrollment\n\n\n\nALC increased within one treatment cycle, with mean ALC rising to ≥ 1.4 x 103/uL (p","length":624,"tagName":"div"}]